<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35554535</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1536-4844</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Inflammatory bowel diseases</Title>
          <ISOAbbreviation>Inflamm Bowel Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Genetic Profiling of Colorectal Carcinomas of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">izac087</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/ibd/izac087</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) run a 10-fold increased risk of developing colorectal cancer (CRC) compared to patients with IBD only. The aim of this study was to perform an extensive screen of known carcinogenic genomic alterations in patients with PSC-IBD, and to investigate whether such changes occur already in nondysplastic mucosa.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Archival cancer tissue and nondysplastic mucosa from resection specimens of 19 patients with PSC-IBD-CRC were characterized, determining DNA copy-number variations, microsatellite instability (MSI), mutations on 48 cancer genes, and CpG island methylator phenotype (CIMP). Genetic profiles were compared with 2 published cohorts of IBD-associated CRC (IBD-CRC; n = 11) and sporadic CRC (s-CRC; n = 100).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Patterns of chromosomal aberrations in PSC-IBD-CRC were similar to those observed in IBD-CRC and s-CRC, MSI occurred only once. Mutation frequencies were comparable between the groups, except for mutations in KRAS, which were less frequent in PSC-IBD-CRC (5%) versus IBD-CRC (38%) and s-CRC (31%; P = .034), and in APC, which were less frequent in PSC-IBD-CRC (5%) and IBD-CRC (0%) versus s-CRC (50%; P &lt; .001). Cases of PSC-IBD-CRC were frequently CIMP positive (44%), at similar levels to cases of s-CRC (34%; P = .574) but less frequent than in cases with IBD-CRC (90%; P = .037). Similar copy number aberrations and mutations were present in matched cancers and adjacent mucosa in 5/15 and 7/11 patients, respectively.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The excess risk of CRC in patients with PSC-IBD was not explained by copy number aberrations, mutations, MSI, nor CIMP status, in cancer tissue, nor in adjacent mucosa. These findings set the stage for further exome-wide and epigenetic studies.</AbstractText>
          <CopyrightInformation>© 2022 Crohn’s &amp; Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s &amp; Colitis Foundation.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>de Krijger</LastName>
            <ForeName>Manon</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-9655-5382</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carvalho</LastName>
            <ForeName>Beatriz</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0003-4903-399X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rausch</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bolijn</LastName>
            <ForeName>Anne S</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Delis-van Diemen</LastName>
            <ForeName>Pien M</ForeName>
            <Initials>PM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tijssen</LastName>
            <ForeName>Marianne</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Engeland</LastName>
            <ForeName>Manon</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mostafavi</LastName>
            <ForeName>Nahid</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Biostatistics Unit of Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bogie</LastName>
            <ForeName>Roel M M</ForeName>
            <Initials>RMM</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dekker</LastName>
            <ForeName>Evelien</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Masclee</LastName>
            <ForeName>Ad A M</ForeName>
            <Initials>AAM</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Verheij</LastName>
            <ForeName>Joanne</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meijer</LastName>
            <ForeName>Gerrit A</ForeName>
            <Initials>GA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ponsioen</LastName>
            <ForeName>Cyriel Y</ForeName>
            <Initials>CY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Inflamm Bowel Dis</MedlineTA>
        <NlmUniqueID>9508162</NlmUniqueID>
        <ISSNLinking>1078-0998</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <OtherAbstract Type="plain-language-summary" Language="eng">
        <AbstractText>The excessive risk of colorectal carcinoma (CRC) in patients with both primary sclerosing cholangitis and inflammatory bowel disease (IBD) was not explained by an extensive screen of copy number aberrations, mutations, microsatellite instability, and CpG island methylator phenotype status when compared with patients with IBD-CRC and sporadic CRC.</AbstractText>
        <CopyrightInformation>© 2022 Crohn’s &amp; Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s &amp; Colitis Foundation.</CopyrightInformation>
      </OtherAbstract>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">colorectal cancer</Keyword>
        <Keyword MajorTopicYN="N">inflammatory bowel disease</Keyword>
        <Keyword MajorTopicYN="N">primary sclerosing cholangitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>15</Hour>
          <Minute>51</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35554535</ArticleId>
        <ArticleId IdType="doi">10.1093/ibd/izac087</ArticleId>
        <ArticleId IdType="pii">6584483</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
